ONE-WAYDated event · through FY2025-H1

Obtaining a License to Manufacture and Market Regenerative Medical Products

A project to establish the personnel and quality management systems, including GQP, GVP and responsible personnel, and obtain a license to manufacture and market regenerative medical products, in preparation for the in-house manufacture and marketing of Telomelysin (OBP-301).

Companies2How many companies write about this.

Threads2One company can carry more than one thread here.

PeriodFY2023-Q3 →Last written FY2025-H1

Directionhelps2 helps · 0 hurts · 0 flat